Our aim was to construct and characterize 111 In-nuclear translocation sequence (NLS)-7G3, an Auger electron-emitting radioimmunotherapeutic agent that preferentially recognizes the expression of CD123 (interleukin-3 receptor [IL-3R] a-subchain) in the absence of CD131 (IL-3R b-subchain) displayed by leukemia stem cells. Methods: Monoclonal antibody 7G3 was modified with 13-mer peptides [CGYGPKKKRKVGG] harboring the NLS of SV-40 large T-antigen and with diethylenetriaminepentaacetic acid for labeling with 111 In. Immunoreactivity was evaluated in a competition radioligand binding assay and by flow cytometry. Nuclear localization of 111 In-NLS-7G3 was studied by cell fractionation in CD123 1 /CD131 2 acute myelogenous leukemia (AML)-3, -4, and -5 cells or in primary AML or normal leukocytes. Micro-SPECT was performed in nonobese diabetic (NOD)/severe combined immune deficient (SCID) mice engrafted subcutaneously with Raji-CD123 tumors or with disseminated AML-3 or -5 cells. The cytotoxicity of 111 In-NLS-7G3 on AML-5 cells was studied after 7 d in culture by trypan blue dye exclusion. DNA damage was assessed using the g-H2AX assay. Results: NLS-7G3 exhibited preserved CD123 immunoreactivity (affinity, 4.6 nmol/L). Nuclear importation of 111 In-NLS-7G3 in AML-3, -4, or -5 cells was specific and significantly higher than unmodified 111 In-7G3 and was greater in primary AML cells than in normal leukocytes. Rapid elimination of 111 In-NLS-7G3 in NOD/SCID mice prevented imaging of subcutaneous Raji-CD123 tumors. This phenomenon was Fc-dependent and IgG 2a isotype-specific and was overcome by the preadministration of excess IgG 2a or using 111 In-NLS-7G3 F(ab9) 2 fragments. AML-3 and -5 cells were engrafted into the bone marrow or spleen or at extramedullary sites in NOD/SCID mice. Micro-SPECT/CT with 111 In-NLS-7G3 F(ab9) 2 showed splenic involvement, whereas foci of disease were seen in the spine or femur or at extramedullary sites in the brain and lymph nodes using 111 In-NLS-7G3 IgG 2a . The viability of AML-5 cells was reduced by exposure in vitro to 111 In-NLS-7G3; this reduction was associated with an increase in unrepaired DNA double-strand breaks. Conclusion: 111 In-NLS-7G3 is a promising novel Auger electron-emitting radioimmunotherapeutic agent for AML aimed at the leukemia stem cell population. Micro-SPECT/CT was useful for visualizing the engraftment of leukemia in NOD/ SCID mice.
inate from a primitive malignant stem cell that shares the CD34 1 /CD38 2 phenotype of normal hematopoietic stem cells (1) . These leukemia stem cells (LSCs), discovered by Bonnet and Dick in 1997 (2) , are present at a low frequency (,1%) but are resistant to cytotoxic therapy because of expression of multidrug resistance transporters (3, 4) . Consequently, despite the fact that remissions are induced in 60%-70% of patients by intensive chemotherapy combined with hematopoietic stem cell transplantation, only 1 in 5 AML patients survives more than 3 y (5). Therapeutic approaches that eradicate the LSC population would produce more durable remissions, and potentially cure (1) . Our laboratory is exploring a novel radioimmunotherapeutic strategy to eradicate LSCs, which relies on the nanometer-to micrometer-range Auger electrons emitted by 111 In complexed to the anti-CD123 murine IgG 2a monoclonal antibody (mAb) 7G3. These electrons cause lethal DNA damage in cells, particularly if they are released near the nucleus (6). Jordan et al. reported that LSCs display the interleukin-3 receptor (IL-3R) a-subchain (CD123) in the absence of the b-chain, whereas normal hematopoietic stem cells display functional IL-3R (CD123/CD131) (7) . mAb 7G3 is a murine IgG 2a that preferentially binds CD123 on AML blasts and LSCs with an affinity (K d , 0.9 nM), which is 100-fold higher than IL-3 itself, whereas its affinity for the functional IL-3R is 3-fold lower than that of IL-3 (8) . mAb 7G3 is internalized after CD123 binding, which inserts 111 In into leukemia cells; to promote nuclear translocation, however, we modified 7G3 with peptides [CGYGPKKKRKVGG] , which harbor the nuclear localization sequence (NLS) of SV-40 large T-antigen (underlined) (9) . We report that 111 In-NLS-7G3 caused DNA doublestrand breaks in vitro in CD123 1 /CD131 2 AML cells, diminishing their viability when compared with untreated cells. In addition, we describe a practical and robust nonobese diabetic (NOD)/severe combined immune deficient (SCID) mouse model of AML established by engrafting leukemia cell lines that share the CD123 1 /CD131 2 phenotype of LSCs. This model was instrumental in our ability to study tracking of 111 In-NLS-7G3 to sites of leukemia in the bone marrow (BM) and spleen or at other extramedullary (EM) sites. 111 In emits 2 highly abundant g-photons (Eg, 171 keV [90%] and 245 keV [94%]), in addition to the Auger electron emissions, that can be imaged by SPECT. Thus, high-spatial-resolution and high-sensitivity multipinhole micro-SPECT/CT was used to visualize the uptake of 111 In-NLS-7G3 at sites of leukemia in this model. Our results suggest that 111 In-NLS-7G3 is a promising radioimmunotherapeutic agent for eradication of the LSC population in AML. Moreover, micro-SPECT/CT with 111 In-NLS-7G3 permits assessment of dissemination of AML cells to survival niches in NOD/SCID mice.
MATERIALS AND METHODS mAbs and Cells
Murine anti-CD123 mAb 7G3 and isotype-matched BM4 IgG 2a were provided by CSL Ltd. Murine IgG 1 was purchased from AbD Serotec. F(ab9) 2 fragments were generated using immobilized pepsin-agarose beads (Pierce). Wild-type Raji cells and CD123-transfected clone (Raji-CD123) and Chinese hamster ovary (CHO)-CD123 cells were provided by CSL Ltd. AML lines 3, 4, and 5 were provided by Dr. Mark Minden (Ontario Cancer Institute) (10) .
Radioimmunoconjugates mAbs 7G3 and BM4 or F(ab9) 2 fragments were modified with diethylenetriaminepentaacetic acid (DTPA) and NLS peptides [CGYGPKKKRKVGG] as previously reported (11) . Approximately 100-300 mg of DTPA-NLS-mAbs or F(ab9) 2 fragments in 1 M sodium acetate buffer, pH 6.0, were labeled with 74 MBq of 111 InCl 3 (MDS-Nordion) at room temperature for 1 h. 111 In-labeled radioimmunoconjugates were purified on a Sephadex G-50 minicolumn (BioRad) eluted with phosphate-buffered saline, pH 7.4. The radiochemical purity was measured by instant thinlayer silica gel chromatography developed in 100 mM sodium citrate, pH 5.0, or by high-performance liquid chromatography on a Biosep SEC-S2000 column (Phenomenex Inc.).
Cell-Binding Assays
111 In-DTPA-7G3 (0.4 nM) was incubated for 1 h at 4°C with 1 · 10 5 CHO cells transfected with CD123 per well in a 24-well plate in the presence of 0.2-225 nM NLS-7G3 or 7G3. The K d value was obtained by fitting the percentage 111 In bound versus log concentration of inhibitor (nmol/L). Flow cytometry was performed by incubating 1 · 10 5 Raji or Raji-CD123 cells in 100 mL of phosphate-buffered saline with 10 mg of nonlabeled NLS-7G3 or NLS-BM4 on ice for 30 min, rinsing, and following with 2 mL of phycoerythrin-conjugated antimouse Fc F(ab9) 2 fragments for 30 min. Cells were counted (.10,000 events) in a flow cytometer (Beckman Coulter LSR II).
Nuclear Importation
The nuclear localization of 111 In-NLS-7G3 in AML cells, primary AML, and leukocytes from a healthy donor was measured at 2 h after incubation with the cells at 37°C by subcellular fractionation and compared with that of 111 In-NLS-BM4 or 111 In-7G3, as previously reported (11) . Nuclear radioactivity was expressed as a percentage of 111 In added to cells in the wells.
Imaging of NOD/SCID Mice with Raji-CD123 Tumors
Raji-CD123 tumors were established by subcutaneous inoculation of 5 · 10 6 cells into NOD/SCID mice. Tumor-bearing mice were imaged using a NanoSPECT/CT (Bioscan) camera. Mice were injected intravenously (tail) with 20- 111 In-labeled F(ab9) 2 from the blood was determined after injection of 0.24-0.87 MBq (10 mg) in NOD/SCID or BALB/c mice. Blood samples were collected from the saphenous vein at 5, 15, and 30 min and at 1, 2, 3, 19, 24, 48, and 72 h after injection. The blood-radioactivityversus-time curves were fitted to a 1-exponential decay, and the half-life (t 1/2 ) was estimated using Scientist software (version 2.01; Micromath). The radioactivity in blood, tumor, and normal organs was measured at 72 h after injection for 111 In-NLS-7G3 and at 48 h for F(ab9) 2 . All animal studies were approved by the Animal Care Committee at the University Health Network (protocol 864.5).
AML Cell Line Engraftment in NOD/SCID Mouse Model
AML-3, -4, or -5 cells sharing the CD123 1 /CD131 2 phenotype of LSCs were engrafted into NOD/SCID mice. NOD/SCID mice received 300 cGy of g-radiation 24 h before intravenous inoculation with 2-5 · 10 6 AML-3, -4, or -5 cells. Engraftment was determined by measuring the proportion of human cells in the BM and spleen and other EM sites by flow cytometry using allophycocyanin-antihuman CD45 antibodies (Beckman Coulter) at 26-46 d after cell inoculation, as previously reported (12) . Further phenotypic characterization was performed using fluorescein isothiocyanate-anti-CD34, phycoerythrin-anti-CD123, phycoerythrin-anti-CD131 antibodies (BD Biosciences), and peridinin chlorophyll protein complex-antiCD38 antibodies (Biolegend). Hemoglobin, erythrocyte (red blood cells), leukocyte (white blood cells), and platelet counts were measured in a blood sample obtained by cardiac puncture.
Micro-SPECT/CT of AML Engraftment
Imaging studies were performed in NOD/SCID mice engrafted with AML-3 cells and injected with 111 In-NLS-7G3 F(ab9) 2 or 111 In-NLS-7G3. Alternatively, NOD/SCID mice engrafted with AML-5 cells were injected with 111 In-NLS-7G3 with preadministration of BM4 IgG 2a . Western blotting for human CD45 on excised tissues from imaged mice was performed by electrophoresing 10 mg of tissue protein on a 4%-20% Tris HCl mini-gel (BioRad), transferring onto a nitrocellulose membrane (BioRad), and probing with goat antihuman CD45 mAbs (Serotec AbD). The immunoblot was developed with murine antigoat horseradish peroxidase-conjugated antibody (Serotec AbD) and imaged by chemiluminescence (Western Lightning; PerkinElmer).
DNA Damage and Cytotoxicity
DNA damage in AML-5 cells was evaluated using the g-H2AX assay as previously reported (13) . Approximately 5 · 10 6 AML-5 cells were incubated with 7.4 MBq (120 nM) of 111 In-NLS-7G3, 111 In-7G3, or unlabeled 7G3 (120 nM) for 24 h. The number of g-H2AX foci per nucleus was calculated for each treatment in 3 microscopic fields. The cytotoxicity of 111 In-NLS-7G3 on AML-5 cells was determined by exposing 1 · 10 6 cells to 1 mL of growth medium alone, 111 In-NLS-7G3 (7.4 MBq, 120 nM), 111 In-acetate (7.4 MBq), or unlabeled 7G3 (120 nM) for 12 h. Cells were centrifuged at 420g for 5 min, and the supernatant was removed. Cells were then resuspended in 1 mL of fresh medium and cultured for 7 d. Cells were recovered and stained with 0.4% trypan blue (Sigma-Aldrich). The percentage cell viability was calculated by dividing the number of cells excluding trypan blue by the total number of cells counted. Comparisons were made to cells exposed to growth medium alone.
Statistical Analysis
Statistical significance in the nuclear translocation, pharmacokinetic, Raji-CD123 xenograft biodistribution, and cytotoxicity studies was determined using a 2-tailed Student t test (P , 0.05). For biodistribution studies in AML engraftment models, the nonparametric Mann-Whitney U test with a 1-tail P value (P , 0.05) or a 2-way ANOVA (P , 0.05) was used.
RESULTS

Radioimmunoconjugates
7G3 and BM4 mAbs were monofunctionalized with DTPA and NLS peptides as previously reported (11 111 In to a radiochemical purity greater than 95% and specific activity of 0.24-0.74 MBq/mg (3.60 · 10 7 -1.11 · 10 8 GBq/mol).
Nuclear Importation NLS modification of 111 In-7G3 achieved 14.7% 6 5.0%, 3.1% 6 2.2%, and 4.2% 6 3.6% importation into the nucleus of AML-3, -4, and -5 cells, respectively, at 2 h at 37°C ( ½Fig: 1 Fig. 1 ). In comparison to unmodified 111 In-7G3, NLS modification significantly increased nuclear radioactivity in AML-3, -4, and -5 cells (P 5 0.019, 0.018, and 0.027, respectively). In primary AML cells, nuclear uptake of 111 In-NLS-7G3 was higher than 111 In-NLS-BM4 (20.9% 6 2.7% vs. 4.8% 6 4.0%; P 5 0.0045; Supplemental Fig. 2) . Moreover, there was lower uptake of 111 In-NLS-7G3 in the nucleus of leukocytes from a healthy donor (2.8% 6 0.7%; P 5 0.0004) than in primary AML cells (Supplemental Fig.  2 ).
Imaging of NOD/SCID Mice with Raji-CD123 Tumors
Raji-CD123 tumors in NOD/SCID mice could not be visualized with 111 In-NLS-7G3 ( ½Fig: 2 Fig. 2A ) at 24 h after injection. There was an unusually rapid elimination of 111 In-NLS-7G3 from the blood, with only 0.2 6 0.1 percentage injected dose per gram (%ID/g) circulating at 72 h after injection ( ½Table 1 Table 1 ). The blood-concentration-versustime curve for 111 In-NLS-7G3 was monoexponential, with a t 1/2 of 7.6 h ( Fig. 2B ; Supplemental Table 1 ). This rapid elimination in NOD/SCID was not present in BALB/c mice (5.0 6 1.4 %ID/g in the blood at 72 h; P 5 0.002). The t 1/2 for 111 In-NLS-7G3 in BALB/c mice (33.0 h) was longer than in NOD/SCID mice. In contrast, there was only a small difference in the t 1/2 of 111 In-NLS-7G3 F(ab9) 2 Table 1 ). At 72 h after injection, there was 0.6 6 0.2 %ID/g versus 0.9 6 0.1 %ID/g in the blood of NOD/SCID or BALB/c mice (P 5 0.060). Preadministration of a 10-fold excess of 7G3 at 24 h after 111 In-NLS-7G3 increased blood radioactivity at 72 h after injection (7.6 6 1.7 %ID/g; Table 1 ) and increased the t 1/2 for 111 In-NLS-7G3 (17.8 h; Supplemental Table 1 ). Preadministration of BM4 increased uptake of 111 In-NLS-7G3 in Raji-CD123 tumors (14.7 6 2.8 %ID/g; Table 1 ) allowing tumor visualization by micro-SPECT/CT (Fig. 2A) . The CD123 dependence of tumor uptake of 111 In-NLS-7G3 was shown by lower uptake in wild-type Raji tumors (2.1 6 0.6 %ID/g; P 5 0.002; Table 1 ). Preadministration of murine IgG 1 did not slow the elimination of 111 In-NLS-7G3 from the blood and did not permit imaging of Raji-CD123 tumors (Supplemental Fig. 3B ). Raji-CD123 tumors were imaged with 111 In-NLS-7G3 F(ab9) 2 without preadministration of BM4 (Fig. 2A) . The specificity of tumor uptake of 111 In-NLS-7G3 F(ab9) 2 was shown by the lower uptake of 111 In-NLS-BM4 F(ab9) 2 in Raji-CD123 tumors (7.2% 6 3.8% vs. 0.3% 6 0.1%; P 5 0.035; Table 1 ). Normal spleen and kidneys were seen on images with 111 In-NLS-7G3 or the F(ab9) 2 fragments, respectively. Figs. 4B-4D ). AML-engrafted mice exhibited lower hemoglobin, red blood cell, and platelet counts and higher white blood cell counts than did healthy nonirradiated or irradiated NOD/SCID mice (Supplemental Figs. 4E-4H ).
Imaging Leukemia Uptake of 111 In-NLS-7G3 F(ab9) 2 in AML-3-Engrafted Mice Biodistribution studies revealed that there was higher mean uptake of 111 In-NLS-7G3 F(ab9) 2 than 111 In-NLS-BM4 F(ab9) 2 in the spleen of AML-3-engrafted mice ( ½Fig: 3 Fig. 3A) , although it did not reach statistical significance possibly because of variable AML engraftment. In 2 representative AML-3-engrafted mice, the spleen was visualized by micro-SPECT/CT with 111 In-NLS-7G3 F(ab9) 2 (Fig.  3B ), but in a representative mouse receiving 111 In-NLS-BM4 F(ab9) 2 the spleen was not seen (Fig. 3B) . Possible EM sites of leukemia were imaged in the orbit of the eye and in an LN in 1 mouse receiving 111 In-NLS-7G3 F(ab9) 2 (Fig. 3B) . Mean uptake of 111 In-NLS-7G3 F(ab9) 2 in the femur including the BM (a site of leukemia) was significantly (P 5 0.047) higher than 111 In-NLS-BM4 F(ab9) 2 (Fig. 3A) . At 48 h after injection, biodistribution studies ( ½Table 2  Table 2 ) revealed significantly greater uptake of 111 In-NLS-7G3 F(ab9) 2 than 111 In-NLS-BM4 F(ab9) 2 in the liver (P 5 0.045) and kidneys (P 5 0.047).
Imaging Leukemia Uptake of 111 In-NLS-7G3 in AML-3-Engrafted Mice
There was significantly greater uptake of 111 In-NLS-7G3 into the spleen (P 5 0.0037) and femur (including the BM; P 5 0.0237) of AML-3-engrafted NOD/SCID mice than nonengrafted (nonirradiated or irradiated) NOD/SCID mice at 72 h after injection ( ½Fig: 4 Fig. 4A ; Table 2 ). The mean uptake of 111 In-NLS-7G3 in the femur and spleen of nonirradiated and nonengrafted NOD/SCID mice was 3.8 6 0.6 %ID/g and 38.1 6 2.5 %ID/g, respectively. The radioactivity in the blood of AML-3-engrafted mice injected with 111 In-NLS-7G3 was significantly higher (P 5 0.0015) than in either nonengrafted group. In 3 representative AML-3-engrafted mice, multiple small foci of radioactivity were imaged in the spine, pelvis, and femur (Fig. 4B) . EM leukemia deposits were imaged. Human CD45 1 cells in the BM and spleen and at EM sites were detected by Western blotting or immunohistochemistry (Supplemental Fig. 5 ).
Imaging Leukemia Uptake in AML-5-Engrafted Mice
In NOD/SCID mice engrafted with AML-5 cells, preadministration of a 5-fold excess of BM4 24 h before 111 In-NLS-7G3 resulted in higher femoral uptake (including the BM) than 111 In-NLS-BM4 ( ½Fig: 5 (Fig. 5B) depicts AML growth at an epiphyseal region in the femur also seen on CT (Fig. 5B) . Imaging demonstrated uptake of 111 In-NLS-7G3 in these regions (Fig. 5B ), compared with a mouse injected with 111 In-NLS-BM4 (Fig. 5C ).
DNA Damage and Cytotoxicity
The viability of 1 · 10 6 AML-5 cells exposed to 111 In-NLS-7G3 and cultured for 7 d was diminished by 111 In-NLS-7G3, compared with cells exposed to growth medium alone ( ½Fig: 6 Fig. 6A ). There was no significant effect on the viability of AML-5 cells exposed to noninternalized 111 In-acetate or unlabeled 7G3 (Fig. 6A) . AML-5 cells exposed to 111 In-NLS-7G3 showed an increase in g-H2AX foci representing unrepaired DNA double-strand breaks in the nucleus (4.8 6 0.2 foci per nucleus; Fig. 6B ), compared with cells exposed to growth medium (0.2 6 0.3 foci per nucleus; Fig. 6 E; P 5 0.0001). Cells exposed to 111 In-7G3 also exhibited an increase in g-H2AX foci (3.0 6 0.9 foci per nucleus; Fig. 6C ; P 5 0.006), compared with medium-exposed cells. There appeared to be a higher number of g-H2AX foci in cells treated with unlabeled 7G3 (2.6 6 1.5; Fig. 6D ), compared with cells exposed only to medium, but this difference was not significant (P 5 0.06). are promising for further study of 111 In-NLS-7G3 for Auger electron radioimmunotherapy of AML, they additionally show that CD123-targeted AML engraftment in NOD/ SCID mice can be visualized by micro-SPECT/CT. At present, AML engraftment is routinely assessed in NOD/ SCID mice by sacrificing the mice and determining the proportion of human cells ex vivo in the BM or spleen by flow cytometry. This does not permit longitudinal monitoring of individual mice to evaluate the kinetics of engraftment or to study the effects of treatment on the leukemic burden and, especially, to identify recurrence after treatment, which is the major challenge in treating AML in humans (5). Micro-SPECT/CT revealed a pharmacokinetic barrier that prevented effective delivery of 111 In-NLS-7G3 to Raji-CD123 xenografts that was IgG 2a -specific and Fcmediated. The rapid elimination of 111 In-NLS-7G3 in NOD/SCID mice but not in BALB/c mice was most likely due to low levels of circulating IgG 2a which previously caused sequestration of mAbs of this isotype by FcgRI receptors in the liver and spleen (14) . Here, we report this phenomenon in NOD/SCID mice and emphasize its importance for evaluating 7G3 (and other IgG 2a mAbs) for treatment of AML in this model. Jin et al. found that treatment of NOD/SCID mice with unlabeled 7G3 at 6 h after inoculation of AML cells abrogated engraftment, whereas treatment at 24 h was less effective, and treatment at 28 d decreased the leukemic burden in only 2 of 5 groups of mice (12) . These results imply that administration of 7G3 shortly after cell inoculation provided the greatest access to circulating LSCs and minimized the effects of sequestration by the spleen. In contrast, the effectiveness of 7G3 in mice with established leukemia could be reduced by uptake in the liver and spleen before reaching leukemia cells in the BM. In our study, preadministration of an excess of irrelevant BM4 IgG 2a slowed the elimination of 111 In-NLS-7G3 and greatly increased uptake into Raji-CD123 tumors. Normal-organ sequestration of radiolabeled mAbs is an important consideration in humans, and analogous preloading strategies have proven effective for decreasing liver uptake and promoting the BM accumulation of 111 In-labeled YAML568 anti-CD45 IgG 2a mAbs in patients with AML (15) . Increased BM uptake was associated with complete remission in 4 patients undergoing hematopoietic stem cell transplantation in which 90 Y-labeled YAML568 was used in the conditioning regimen. Others have also found rapid elimination of radiolabeled mAbs that diminished their effectiveness for BM conditioning in AML (16, 17) .
Despite the antileukemic effects of unlabeled 7G3 in NOD/SCID mice (12), a phase I trial of CSL360, a chimeric IgG 1 analog of 7G3, reported only 1 complete response among 26 patients with relapsed, refractory, or high-risk AML treated at doses of 0.1-10 mg/kg (18) . Combining 7G3 or CSL360 mAbs with 111 In and our nuclear localization strategy may improve their effectiveness. We previously reported that 111 In-NLS-HuM195 anti-CD33 mAbs killed HL-60 leukemia cells and retained their cytotoxicity toward HL-60/MX-1 cells with mitoxantrone resistance or primary AML specimens with multidrug resistance phenotype (19) . This finding suggests that multidrug resistance transporter expression, which is a characteristic of LSCs (3,4), may not be an impediment to treatment with 111 Inlabeled mAbs. A challenge for radioimmunotherapy of AML with 111 In-NLS-7G3, however, is low CD123 RGB RGB expression (4 · 10 4 sites per cell) (20) , possibly explaining the inability in our study to diminish the viability of AML-5 cells by more than 4-fold using 111 In-NLS-7G3 with relatively low specific activity (0.24-0.74 MBq/mg). An analogous effect was found for 111 In-NLS-HuM195 on CD33 1 leukemia cells in which a minimum specific activity of 2 MBq/mg was needed for cytotoxicity (19) . Strategies to increase the specific activity of 111 In-NLS-7G3 by conjugation to starburst polyamidoamine dendrimers that permit conjugation to large numbers of DTPA chelators for complexing 111 In may enhance its effectiveness (21) .
Finally, another contribution of our study was the establishment and characterization of a NOD/SCID mouse model that used AML-3, -4, or -5 cell lines that share the CD123 1 /CD131 2 phenotype of LSCs but can be easily maintained in culture. Engraftment of primary AML specimens into the BM and spleen of NOD/SCID mice is a standard model of the disease (22) , but there is high variability in engraftment efficiency (23) (24) (25) (26) (27) . Furthermore, the proportion of CD123 1 cells varies between specimens, and cells from a single specimen cannot be easily expanded in culture to inoculate groups of mice with AML cells that have a predefined level of CD123. Therefore, the establishment of this more practical NOD/SCID mouse model of AML using these cell lines was instrumental in our ability to evaluate the delivery of 111 In-NLS-7G3 and its F(ab9) 2 fragments to leukemia in the BM and spleen and at EM sites.
CONCLUSION
111 In-NLS-7G3 was specifically bound, internalized, and translocated to the nucleus of AML cells displaying the CD123 1 /CD131 2 phenotype of LSCs. Emission of nanometer to micrometer Auger electrons near DNA caused double-strand breaks, reducing the viability of AML cells. 111 In-NLS-7G3 and its F(ab9) 2 fragments specifically localized in subcutaneous Raji-CD123 tumor xenografts as well as at sites of leukemia in the BM and spleen or at other EM sites in NOD/SCID mice. These results are promising for further study of 111 In-NLS-7G3 for treatment of AML.
DISCLOSURE STATEMENT
The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.
